Nothing Special   »   [go: up one dir, main page]

MX2022009905A - Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto. - Google Patents

Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto.

Info

Publication number
MX2022009905A
MX2022009905A MX2022009905A MX2022009905A MX2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A
Authority
MX
Mexico
Prior art keywords
bladder cancer
invasive bladder
muscle invasive
treatment
tyrosine kinase
Prior art date
Application number
MX2022009905A
Other languages
English (en)
Inventor
Manish Monga
Mahadi Ali Baig
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022009905A publication Critical patent/MX2022009905A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se describen métodos para tratar el cáncer de vejiga sin invasión muscular de riesgo alto (CVSIM-RA) que comprenden administrar un inhibidor del receptor del factor de crecimiento de fibroblastos (FGFR, por sus siglas en inglés). También se describen métodos para tratar el cáncer de vejiga sin invasión muscular de riesgo intermedio (CVSIM-RI) que comprenden administrar un inhibidor de FGFR.
MX2022009905A 2020-02-12 2021-02-11 Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto. MX2022009905A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062975547P 2020-02-12 2020-02-12
US202063018914P 2020-05-01 2020-05-01
US202063118475P 2020-11-25 2020-11-25
PCT/EP2021/053385 WO2021160764A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Publications (1)

Publication Number Publication Date
MX2022009905A true MX2022009905A (es) 2022-08-25

Family

ID=74666675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009905A MX2022009905A (es) 2020-02-12 2021-02-11 Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto.

Country Status (13)

Country Link
US (1) US20230110113A1 (es)
EP (1) EP4103185A1 (es)
JP (1) JP2023513704A (es)
KR (1) KR20220140781A (es)
CN (1) CN115103678A (es)
AU (1) AU2021220285A1 (es)
BR (1) BR112022015827A2 (es)
CA (1) CA3162962A1 (es)
IL (1) IL295514A (es)
JO (1) JOP20220182A1 (es)
MX (1) MX2022009905A (es)
TW (1) TW202143970A (es)
WO (1) WO2021160764A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240350485A1 (en) * 2021-10-12 2024-10-24 Taris Biomedical Llc Erdafitinib formulations and systems for intravesical administration
TW202400174A (zh) * 2022-02-18 2024-01-01 美商塔里斯生物醫學有限責任公司 用於膀胱內施用的Erdafitinib調配物及滲透系統
WO2024170495A1 (en) * 2023-02-13 2024-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2024173377A1 (en) * 2023-02-13 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer
WO2024173716A1 (en) * 2023-02-17 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2262403C (en) 1995-07-31 2011-09-20 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AU2006249847B2 (en) 2005-05-23 2012-12-20 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
ES2912567T3 (es) 2014-09-26 2022-05-26 Janssen Pharmaceutica Nv Uso de paneles de genes mutantes de FGFR en la identificación de pacientes con cáncer que serán responsable al tratamiento con un inhibidor de FGFR
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
PT3576740T (pt) * 2017-12-20 2023-08-18 Janssen Pharmaceutica Nv Tratamento de cancro

Also Published As

Publication number Publication date
JOP20220182A1 (ar) 2023-01-30
BR112022015827A2 (pt) 2022-10-04
IL295514A (en) 2022-10-01
WO2021160764A1 (en) 2021-08-19
JP2023513704A (ja) 2023-04-03
CA3162962A1 (en) 2021-08-19
KR20220140781A (ko) 2022-10-18
US20230110113A1 (en) 2023-04-13
EP4103185A1 (en) 2022-12-21
CN115103678A (zh) 2022-09-23
TW202143970A (zh) 2021-12-01
AU2021220285A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
JOP20220182A1 (ar) مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة
CR20220258A (es) Inhibidores de kras g12c
PH12021550296A1 (en) Substituted indoles and methods of use thereof
MX2022015410A (es) Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos.
MX2023007793A (es) Compuestos de indazol como inhibidores de cinasas.
MX2013004086A (es) Metodos para inhibir proliferacion celular en cancers accionados por egfr.
WO2016161410A3 (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
MX2021003517A (es) Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
CR10188A (es) Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata
JOP20210260A1 (ar) مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية
EA201170660A1 (ru) Избирательная для erbb-3 (her3) комбинированная терапия
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
JOP20220329A1 (ar) مضاد مستقبل crf1 لعلاج فرط تنسج الكظر الخلقي
MX2023012095A (es) Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
EP3888643A4 (en) THERAPEUTIC AND PROPHYLACTIC PROCEDURE FOR ENDOCRINE THERAPY TUMORS BY COMBINED USE OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR WITH ENDOCRINE THERAPY
MX2021007554A (es) Terapia de combinacion para el tratamiento de cancer.
MX2022014903A (es) Tki de egfr para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
MX2021013982A (es) Compuestos para inhibir la quinasa del egfr, metodos de preparacion y usos de los mismos.
MX2024009018A (es) Compuestos y su uso en el tratamiento del cancer.
EP4097140A4 (en) USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCER WITH NRG1 FUSIONS
IL315848A (en) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
MX2021012130A (es) Combinaciones de inhibidores de transcripción e inhibidores de punto de control inmuneitario para el tratamiento de enfermedad.